A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the centre of a drug pricing row after Britain’s health cost agency declared that it is still too expensive.
The stand-off shows how the price of medicines is as pressing and emotive an issue in Europe as in the United States, where Democratic presidential candidate Hillary Clinton has promised to clamp down on alleged profiteering by the drug industry.
{iframe}http://www.reuters.com/article/2015/11/17/pharmaceuticals-pricing-roche-idUSL8N13B32520151117{/iframe}